What Your Rivvet Emails Look Like
Each alert brings you one study at a glance — why it's relevant, what's new, and a link to discuss it with the right specialist.
Continuous Metformin Monotherapy and Long-Term Cardiovascular Outcomes in Adults With Type 2 Diabetes: A Multicenter Cohort Study
Why This Might Apply to You
You selected Type 2 Diabetes. This study examined metformin use in adults with Type 2 Diabetes aged 45–70.
What's New
Adults on continuous metformin monotherapy showed 22% fewer major cardiovascular events over 10 years compared to those started on other first-line oral glucose-lowering medications.
A multicenter retrospective cohort study of 14,320 adults with Type 2 Diabetes (mean age 56, 48% female) compared long-term cardiovascular outcomes in patients maintained on metformin monotherapy versus those switched to sulfonylureas or DPP-4 inhibitors within the first two years of treatment. Over a median follow-up of 10.3 years, the metformin group was associated with a lower incidence of major adverse cardiovascular events (HR 0.78; 95% CI, 0.71–0.86; P<0.001).
This research may be relevant to your interests — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.
Know someone who'd find this useful?
Share Rivvet Health with a friend →For every friend who subscribes, you'll get priority access to breaking research alerts.
Unsubscribe · Manage Preferences
You received this because you selected Type 2 Diabetes.
Rivvet may earn a referral fee if you book through our Zocdoc links.
Efficacy of Spironolactone vs. Oral Isotretinoin for Persistent Adult Acne in Women: A Randomized Controlled Trial
Why This Might Apply to You
You selected Acne. This study focused on persistent adult acne treatment in women aged 25–40.
What's New
Low-dose spironolactone achieved comparable acne clearance rates to low-dose isotretinoin in women with persistent adult acne, with fewer reported side effects over 24 weeks.
A double-blind randomized controlled trial of 316 women aged 25–40 with moderate-to-severe persistent acne compared low-dose spironolactone (100 mg/day) to low-dose isotretinoin (20 mg/day) over 24 weeks. Both groups demonstrated similar reductions in inflammatory lesion count (−63% vs. −68%, P=0.12 for non-inferiority). The spironolactone group reported fewer mucocutaneous side effects (18% vs. 41%, P<0.001).
This research may be relevant to your interests — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.
Know someone who'd find this useful?
Share Rivvet Health with a friend →For every friend who subscribes, you'll get priority access to breaking research alerts.
Unsubscribe · Manage Preferences
You received this because you selected Acne.
Rivvet may earn a referral fee if you book through our Zocdoc links.